San Antonio 2020 update —the top 3 surgical abstracts

SummaryThe San Antonio Breast Cancer Symposium is one of the largest meetings addressing the treatment of breast cancer patients; therefore, the meeting is of high interest for breast cancer specialists from around the world.From the meeting in 2020, which was held virtually, I have picked the top three surgical abstracts to show new developments in the surgical treatment of breast cancer patients.The first abstract addresses the question of whether an axillary dissection is necessary or not, in a selected patient cohort. The results, even after a short follow-up time, could confirm the findings of the ACOZOG Z 0011 trial.The second abstract refers to the question of whether sentinel node biopsy is always mandatory in older patients with hormone-receptor-positive breast cancer.Finally, the third abstract focuses on a trial dedicated to the sentinel lymph node after neoadjuvant chemotherapy.These three abstracts show the importance of the surgical management of the axilla, under special circumstances.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Condition:   Breast Cancer Female Intervention:   Procedure: sentinel lymph node biopsy or targeted axillary dissection alone Sponsor:   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Intervention:   Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Female Intervention:   Procedure: sentinel lymph node biopsy or targeted axillary dissection alone Sponsor:   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Intervention:   Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Female Intervention:   Procedure: sentinel lymph node biopsy or targeted axillary dissection alone Sponsor:   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Intervention:   Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Oncotarget. 2021 Nov 23;12(24):2388-2403. doi: 10.18632/oncotarget.28135. eCollection 2021 Nov 23.ABSTRACTNeutrophils are prominent immune components of tumors, having either anti-tumor (N1) or pro-tumor activity (N2). Circulating neutrophils, divided into high density neutrophils (HDN) and low density neutrophils (LDN), functionally mirror those N1 and N2 cells, respectively. LDN are rare in non-pathological conditions, but frequent in cancer, exhibiting a pro-tumor phenotype. These findings have been mainly demonstrated in animal models, thus proper validation in humans is still imperative. Here, we observed that LDN wer...
Source: Oncotarget - Category: Cancer & Oncology Authors: Source Type: research
Initially implemented in clinical practice for the treatment of locally advanced breast cancer (BC) patients, the use of neoadjuvant treatment has progressively increased over the last decades and is nowadays considered the standard of care for many early BC patients as well [1,2]. In this context, neoadjuvant chemotherapy (NCT) is widely used to downstage initially operable BCs, increasing the rates of conservative surgery[3]; however, it is well-known that the magnitude of response to NCT varies significantly according to breast cancer subtype.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
Bajor Breast cancer (BC) has traditionally been considered to be not inherently immunogenic and insufficiently represented by immune cell infiltrates. Therefore, for a long time, it was thought that the immunotherapies targeting this type of cancer and its microenvironment were not justified and would not bring benefits for breast cancer patients. Nevertheless, to date, a considerable number of reports have indicated tumor-infiltrating lymphocytes (TILs) as a prognostic and clinically relevant biomarker in breast cancer. A high TILs expression has been demonstrated in primary tumors, of both, HER2-positive BC and tr...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
A correction to this paper has been published: https://doi.org/10.1245/s10434-021-09771-9
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy